Using Patient Perspectives to Inform Better Clinical Trial Design and Conduct: Current Trends and Future Directions.
Journal
Pharmaceutical medicine
ISSN: 1179-1993
Titre abrégé: Pharmaceut Med
Pays: New Zealand
ID NLM: 101471195
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
accepted:
19
12
2022
medline:
14
4
2023
pubmed:
19
1
2023
entrez:
18
1
2023
Statut:
ppublish
Résumé
The approach to patient engagement (PE) in drug development has changed rapidly due to many factors, including the complexity of innovative drugs and the need to demonstrate outcomes of relevance to patients, the desire to show 'value add' of PE, and the pandemic-related changes to how clinical trials are run, e.g., decentralised studies. In parallel, there have been changes in technology-assisted ways of running clinical trials, capturing patient health outcomes and preferences, an increasing societal demand for diversity and inclusion, and efforts to improve clinical trial efficiency, transparency, and accountability. Organisations are beginning to monitor PE activities and outcomes more effectively to learn and inform future PE strategies. As a result, these factors are facilitating the incorporation of patients' lived experience, preferences and needs into the design and running of clinical trials more than ever before. In this paper, the authors reflect upon these last few years, the emerging trends and their drivers, and where we may expect PE in clinical research to progress in the near future.
Identifiants
pubmed: 36653601
doi: 10.1007/s40290-022-00458-4
pii: 10.1007/s40290-022-00458-4
pmc: PMC9848715
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
129-138Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Health Expect. 2019 Aug;22(4):785-801
pubmed: 31012259
BMC Med Inform Decis Mak. 2019 Oct 4;19(1):189
pubmed: 31585538
J Med Ethics. 2005 Apr;31(4):242-8
pubmed: 15800367
Res Involv Engagem. 2018 May 22;4:17
pubmed: 29796308
Heart. 2003 Mar;89(3):327-8
pubmed: 12591845
Value Health. 2020 Jun;23(6):677-688
pubmed: 32540224
Health Expect. 2021 Apr;24(2):491-506
pubmed: 33629470
Sci Transl Med. 2016 Apr 27;8(336):336ps11
pubmed: 27122611
Contemp Clin Trials. 2022 May;116:106740
pubmed: 35364292
J Infect. 2021 Apr;82(4):84-123
pubmed: 33189774
Arch Intern Med. 2002 Aug 12-26;162(15):1682-8
pubmed: 12153370
Ther Innov Regul Sci. 2018 Mar;52(2):220-229
pubmed: 29714515
Health Expect. 2022 Apr;25(2):744-753
pubmed: 35023267
Am J Public Health. 2010 Apr 1;100 Suppl 1:S105-12
pubmed: 20147682
Clin Ther. 2017 Oct;39(10):1933-1938
pubmed: 28943115
Nat Med. 2022 Aug;28(8):1520-1522
pubmed: 35668180
Health Aff (Millwood). 2019 Mar;38(3):359-367
pubmed: 30830822
Health Serv Insights. 2013 Aug 04;6:61-8
pubmed: 25114561
Semin Arthritis Rheum. 2021 Aug;51(4):919-924
pubmed: 34134892
Health Aff (Millwood). 2013 Feb;32(2):223-31
pubmed: 23381514
Trials. 2020 Sep 11;21(1):784
pubmed: 32917258
Clin Pharmacol Ther. 2022 Aug;112(2):344-352
pubmed: 35488483
Nat Med. 2022 Jan;28(1):18-20
pubmed: 35039659
Biomed Res Int. 2013;2013:787616
pubmed: 24175301
Ther Innov Regul Sci. 2021 Sep;55(5):936-953
pubmed: 33970465
Dementia (London). 2018 Nov;17(8):944-975
pubmed: 30373460
Ethn Dis. 2012 Spring;22(2):226-30
pubmed: 22764647
Med Care. 2015 Jan;53(1):9-17
pubmed: 25494232
Contemp Clin Trials Commun. 2018 Jun 28;11:120-126
pubmed: 30094387
Clin Transl Sci. 2019 May;12(3):218-230
pubmed: 30657253
Am J Respir Crit Care Med. 2021 Aug 1;204(3):e26-e50
pubmed: 34347574
Health Commun. 2022 Aug;37(9):1075-1092
pubmed: 34420460
JAMA. 2018 Jan 23;319(4):337-338
pubmed: 29285540
Contemp Clin Trials Commun. 2018 Aug 07;11:156-164
pubmed: 30112460
Clin Pharmacol Ther. 2019 May;105(5):1148-1155
pubmed: 29901216
Ther Innov Regul Sci. 2015 Nov;49(6):929-939
pubmed: 26539338
Value Health. 2017 Feb;20(2):286-291
pubmed: 28237211
Health Expect. 2021 Apr;24(2):601-616
pubmed: 33599067
Trials. 2021 Dec 4;22(1):880
pubmed: 34863265
Ther Innov Regul Sci. 2017 Jan;51(1):29-38
pubmed: 28232876
J Clin Epidemiol. 2016 Dec;80:8-15
pubmed: 27498376
Drug Saf. 2002;25(1):1-5
pubmed: 11820908
JCO Oncol Pract. 2020 Jul;16(7):417-421
pubmed: 32396491
Soc Stud Sci. 1997 Oct;27(5):691-726
pubmed: 11619511
Br J Clin Pharmacol. 2022 Mar;88(3):1031-1042
pubmed: 34296777
Health Expect. 2020 Feb;23(1):5-18
pubmed: 31489988
Ther Innov Regul Sci. 2015 Sep;49(5):745-749
pubmed: 30227037
Patient Prefer Adherence. 2016 Apr 27;10:631-40
pubmed: 27175063
Ther Innov Regul Sci. 2022 Nov;56(6):948-963
pubmed: 35182389
BMJ. 2018 Nov 28;363:k4738
pubmed: 30487232
Front Med (Lausanne). 2020 Mar 20;7:93
pubmed: 32266277
Cancer Cell. 2020 Aug 10;38(2):148-149
pubmed: 32634378
Trials. 2021 May 10;22(1):337
pubmed: 33971916
Ther Innov Regul Sci. 2021 Nov;55(6):1165-1179
pubmed: 34181236
Cochrane Database Syst Rev. 2010 Jan 20;(1):MR000013
pubmed: 20091668
Patient Prefer Adherence. 2017 Jul 31;11:1295-1307
pubmed: 28814837
ESMO Open. 2020 Oct;5(5):e000924
pubmed: 33051193
Ther Innov Regul Sci. 2021 Sep;55(5):1059-1065
pubmed: 34097288
Acta Paediatr. 2019 May;108(5):789-791
pubmed: 30475419
Ther Innov Regul Sci. 2020 Jan;54(1):103-116
pubmed: 32008233
AJOB Empir Bioeth. 2018 Jan-Mar;9(1):39-47
pubmed: 29368998
Am J Public Health. 2014 Feb;104(2):e16-31
pubmed: 24328648
Nat Med. 2022 Jun;28(6):1120-1124
pubmed: 35513530
Med Care. 2018 Oct;56 Suppl 10 Suppl 1:S11-S15
pubmed: 30074943
BMJ. 2003 Jun 7;326(7401):1244-5
pubmed: 12791739
Pharmaceut Med. 2019 Jun;33(3):179-185
pubmed: 31933291
Front Pharmacol. 2019 Dec 03;10:1395
pubmed: 31849657
Health Expect. 2018 Dec;21(6):1035-1045
pubmed: 29858529